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Background. Recent findings show that DNA methylation is susceptible to very preterm 
(VPT) birth and to the experience of the early stay in the Neonatal Intensive Care Unit 
(NICU). The aim of the study was to compare PLAGL1 methylation between VPT and full-
term (FT) infants at birth as well as between VPT infants at discharge and FT infants at birth. 
Methods. DNA was collected from cord blood of 56 VPT and 27 FT infants at birth and from 
peripheral blood in VPT infants at NICU discharge. Socio-demographic and neonatal 
variables were considered. 
Results. PLAGL1 methylation at birth and at discharge were highly correlated in VPT infants. 
Lower methylation emerged in VPT infants at birth and discharge compared to FT 
counterparts. 
Conclusions. PLAGL1 hypo-methylation emerged as a potential epigenetic mark of VPT 
birth. Future research is warranted to assess the functional consequences of PLAGL1 
diminished methylation in VPT infants’ development. 
 
 







Very preterm (VPT) birth (i.e. gestational age < 32 weeks) is associated with many negative 
medical and psychological outcomes both in childhood [1,2] and in adulthood [3]. Notably, 
even in the absence of perinatal injuries and neurodevelopmental deficits, VPT infants show 
different developmental trajectories and disrupted long term outcomes in behavioral, 
physiological and neurological domains [4,5]. 
Despite there being consistent agreement about the fact that VPT birth represents a risk 
factor for further adverse developmental trajectories, the mechanisms associated with 
detrimental outcomes are still under investigation. Researchers to date have investigated 
environmental [6], physiological [7–9] and genetic factors [10,11] associated with altered 
developmental outcomes of VPT birth. Specifically, during the last decade, DNA methylation 
has emerged as a reliable mechanism linking early life adversity with detrimental 
developmental outcome in infancy, childhood and adulthood [12–14]. Despite it is a normal 
regulatory process essential to DNA replication and transcription, DNA methylation occurs 
when a methyl group is covalently attached to cytosine residues in cytosine/guanine (CpG) 
dinucleotides resulting in reduced transcriptional activity (i.e., gene silencing) [15]. When 
methylation occurs in a region involved in gene expression and transcription it is of critical 
relevance as it might produce effects on the actual protein expression and phenotype [15]. 
Despite the fact that DNA methylation is partially regulated by genetic polymorphisms, such 
as the MTHFR (rs1801133GA) [16,17], it has been shown that epigenetic mechanisms are 
highly susceptible to environmental manipulations and birth status. Specifically, alterations of 
DNA methylation – both in terms of increases and decreases – seem to be involved both in 
premature birth per se [18–20] as well as in the negative effects of early exposure to adverse 
environments connected to prematurity (e.g. procedural pain during NICU hospitalization) on 
children’s further development [21,22]. For instance, Cruickshank and colleagues [23] 
analyzed DNA methylation retrospectively in a small sample of 18-year-old preterm birth 
survivors (N = 12) and they documented persistent methylation differences at ten genomic 
loci comparing preterm subjects with full-term matched controls (N = 12). Increased 






methylation at multiple CpG sites including from fetal leukocyte DNA was found in mostly 
very preterm infants (gestational age range: 24-34 weeks) compared to full-term infants 
(gestational age higher than 39 weeks) [24]. 
Imprinted genes, in particular, are considered critical growth effectors responsible for the 
regulation of fetal development [25]. Greater methylation of these genes has been 
associated with fetal growth restriction [26] and reduced DNA methylation at the regulatory 
region of specific imprinted genes (e.g., IGF2, PLAGL1) associates with lower birth weight 
[27–30]. Prematurity has been retrospectively associated with differences in methylation of 
imprinted genes in adults born preterm [31]. Prematurity has been retrospectively associated 
with differences in methylation of imprinted genes in adults born preterm [34]. Moreover, a 
pool of imprinted genes – including IGF2, MEG3, PEG3, and PLAGL1 – have been found to 
be differently methylated in infants with low birth weight (< 2500 grams) compared with 
normal birth weight infants: lower IGF2 methylation was found in infants with low birth weight 
compared to the normal weight counterpart [28]. Nonetheless, in this prospective study the 
sample size widely varied among different birth-weight groups of infants (e.g., low birth 
weight infants, N = 33; normal birth weight infants, N = 475). Other studies investigated DNA 
methylation at imprinted regions in infants born at low birth weight considering the potential 
role of maternal (e.g., depression, physical activity) or biological (e.g., infections) factors 
[28,32,33], but they did not focus specifically on the association between preterm birth and 
differences in DNA methylation between VPT and full-term infants. 
Among imprinted genes, the pleomorphic adenoma gene-like 1 (PLAGL1) appears to be of 
specific interest with regard to prematurity. PLAGL1 is an imprinted gene that functions as a 
suppressor of cell growth [34]. Despite the fact that down regulation of this gene in humans is 
associated with heightened risk of disease, its overexpression is considered a causal factor 
for transient neonatal diabetes mellitus (TNDM) [35]. Notably, Plagl1 deficient mice present 
with embryonic growth restriction [36]. Moreover, PLAGL1 gene down-regulation was found 
in the placenta from intrauterine growth-restriction female, but not male newborns [37]. A 
recent study [32] focused on the methylation differences of a set of imprinted regulatory 






elements in association with preterm birth status (i.e. spontaneous preterm labor, preterm 
premature rupture of membranes, or medically indicated) and placental infections 
(chorioamnionitis or funisitis). Results from Liu and colleagues showed significant 
associations with PLAGL1 methylation only. Specifically, methylation was higher in preterm 
infants whose mothers experienced a placental infection compared to their counterparts 
whose mothers did not experience infection. Interestingly, in another study Liu and 
colleagues [28] found that infants with high birth weight (> 4.500 kg) were associated with 
increased PLAGL1 methylation, however low birth weight infants (< 2.500) were not 
associated with decreased methylation. Surprisingly, thus far, no study has focused on 
PLAGL1 methylation differences between VPT and full-term (FT) infants. In light of the 
aforementioned paucity in the literature, we hypothesized that a pattern of PLAGL1 hypo-
methylation might be linked with prematurity. 
METHODS 
Subjects 
Fifty-six VPT infants (29 females) and twenty-seven FT infants (12 females) participated in 
this prospective longitudinal study investigating genetic and epigenetic vestiges of preterm 
birth and early life adversities (insert after blind review). In the present study, we report data 
on perinatal and discharge methylation of the PLAGL1 gene in VPT infants. VPT infants 
(gestational age ≤ 32 weeks; range 26-32 weeks) were enrolled at the NICU, XXXX (insert 
after blind review). FT infants were recruited at the Pediatric Unit, XXXX (insert after blind 
review) and participated in only perinatal methylation of the gene. Exclusion criteria for VPT 
infants were major brain lesions as documented by cerebral ultra-sound, neuro-sensorial 
deficits, genetic syndromes, and/or major malformations. All FT infants were healthy and had 
no neonatal morbidities or prenatal/perinatal-risk factors. For mothers, exclusion criteria were 
the following: age under 18 years, manifest psychiatric and cognitive pathologies, drug 
addiction, single-parent families. All mothers signed a written informed consent and the study 
was approved by the Ethics Committees of XXXX (insert after blind review) and participating 






hospitals. All the procedures followed the guidelines from the Declaration of Helsinki 2013 
(World Medical Association).  
Protocol 
We collected cord blood at birth from full term and preterm infants whereas peripheral blood 
at discharge was obtained only from preterm infants. Previous research documented that 
mean methylation values of umbilical cord blood cells resembled those from peripheral blood 
cells in healthy individuals [38]. Moreover, cord blood sampling has already been used in 
previous newborn epigenetic studies [11,21,39] and is considered to be non-invasive for 
human newborns. 
Measurements 
Infants’ perinatal data 
Perinatal variables included neonatal (i.e., gestational age, birth weight, gender, Apgar score 
at minute 1, length of NICU stay) and socio-demographic variables (i.e., maternal age, years 
of study, occupation status). According to Hollingshead’s classification [40], socio-
demographic variables were summed up to obtain an index of family socio-economic status 
(SES). SES score ranged from 0 (occupations that do not require high school graduation) to 
90 (occupations that require highly specialized education and training). 
PLAGL1 Methylation assessment 
Genomic DNA was extracted from whole blood with a GenEluta blood genomic kit (Sigma). 
We analyzed a 416 base-pairs CpG-rich portion of the PLAGL1 promoter (chr6:144,328,942-
144,329,357, Human hg19 Assembly), between -285 and +131 relative to the transcriptional 
start site, which contains 57 CpG sites and partially overlaps exon 1. 
Methylation levels were determined in DNA using bisulfite modification followed by PCR 
amplification and NGS. Genomic DNA was extracted from 0.2 ml of each sample using the 
GenElute Blood Genomic DNA kit (Sigma). Bisulfite conversion was performed on 500 ng of 
genomic DNA using the EZ DNA methylation kit (ZymoResearch, Inc, Irvine, CA, USA). 
Primers were designed using Bisulfite Primer Seeker 
(http://www.zymoresearch.com/tools/bisulfite-primer-seeker). The gene-specific forward 5′-






GTAAGAATYGGGTTTGTGGATTTTATATTAG-3′ and reverse 5′-
AACAACCRTACTCACAACTCAACAAC-3′ were used. SureSelect amplicon-specific tails 5′ 
TGTGATCAAGAGACAG 3′ were added to each primer in order to allow synthesis and 
sequencing of SureSelect libraries of methylated fragments. Initial PCR-amplifications were 
performed on 20 ng of bisulfite-treated DNA using Taq Gold (Life Technologies, Inc.). Cycling 
consisted of 5 min pre-activation at 95°C, followed by 35 cycles of 94°C denaturation for 15s, 
58°C annealing for 20s, 72°C elongation for 1.5min. All PCR products were checked on 2% 
agarose gel and treated with Ilustra Exo Pro-STAR (GE Healthcare) to eliminate 
unincorporated primers. Adaptors were subsequently attached to each sample by 8 cycles of 
amplification with a SureSelect Target Enrichment System (Agilent). Samples were again 
treated with Ilustra Exo Pro-STAR, then indexed using specific forward (i5) and reverse (i7) 
index primer combinations and the SureSelect protocol. Approximately equimolar aliquots of 
each product were pooled and purified with AMPure XP beads (Bechman Coulter) following 
Agilent’s protocol. The purified pooled library was quantified on a Bioanalyzer 2100 (Agilent) 
and sequenced on a MiSeq (Illumina) using a v2 Reagent kit, 300 cycles PE. 
In order to analyze the reads, we created a reference sequence of the plus strand of the 
PLAGL1 gene mimicking the results of bisulfite modification. The sequence was indexed with 
the BWA-MEM algorithm. The sequence dictionary was created with the Picard tool 
(http://broadinstitute.github.io/picard/). We aligned the FASTQ sequence reads, cloned 
sequences and assembled contigs with the BWA-MEM algorithm. The resulting SAM files 
were then filtered selecting only reads with a specific cigar value, allowing us to keep only 
reads which align correctly to the region of interest. We converted the SAM files to BAM files 
with SAMtools, indexed and sorted them. The reads were visualized with Integrative Genome 
Viewer (IGV, http://www.broadinstitute.org/igv). Using the IGVtools -count algorithm, we 
obtained the coverage of each base position in the sequenced region. This allowed us to 
calculate the percentage of methylated bases presents at each CpG position. The forward 
read of each sequence covered CpGs 1-17 while the reverse read covered CpGs 38-57. Cpg 
sites 18-37 were omitted from the analysis due to incomplete or null coverage. CpG site 44 






was also omitted because of a C>T polymorphism (rs67300369) in some subjects. The 
average read depth was 17103. It ranged from 15400 to 18497 between CpG sites. As 
expected for an imprinted region, CpGs in any single read were coherent, either all 
methylated or non-methylated. We have verified the coherence for a number of samples by 
calculating the percentage of methylated CpG positions in each read. Completely coherent 
imprinted samples would have only 100% (or 0%) methylated reads. The average 
methylation in the CpG residues of the un-methylated allele reads was 95.6% while 
methylation in the un-methylated allele reads was 1.5%. 
MTHFR polymorphism 
As reported by previous studies, a polymorphic genetic variation of the MTHFR C677T 
(rs1801133) might account for individual variability in the degree of DNA methylation (19,20), 
thus, participant infants were genotyped for this polymorphism. Briefly, 20 ng of genomic 
DNA from each subject was amplified with primers MTHFR-C677T-F (5-
CCTCACCTGGATGGGAAAGA-3) and R (5- GCCCCCAAAGCAGAGGACT-3). The resulting 
304 bp fragment was sequenced from both ends by Sanger sequencing on an ABI3500AV 
(Applied Biosystems). The genotype was dummy coded as follows: 0 = GA and AA, 1 = GG. 
Three subjects (1 VPT and 2 FT infants) had missing information on MTHFR genotype. 
MTHFR distribution was 31 GA/AA and 24 GG in the VPT group and 13 GA/AA and 12 GG 
in the FT group. 
Data analysis 
Neonatal and socio-demographic characteristics were compared between VPT and FT 
groups (0 = VPT; 1 = FT) by means of Wilcoxon independent-sample tests and χ2. Gender (0 
= males, 1 = females) related differences in the two groups were tested by means of 
independent-sample t-test. Prior to the analyses, CpG specific methylation values were 
winsorized to adjust for extreme values and outliers. For the VPT infants’ group, CpG-
specific methylation at each time point (i.e., birth and NICU discharge) was tested for 
bivariate correlation. The association between mean methylation and neonatal variables (i.e. 
gestational age, length of NICU stay) was assessed in VPT infants. We computed different 






analyses to compare VPT and FT infants’ PLAGL1 CpG-specific and mean methylation. For 
what pertains to CpG-specific PLAGL1 methylation, we reported confidence intervals of the t-
test for each site through a forest plot. As for PLAGL1 mean methylation, two regression 
models were performed. Model A evaluated the effect of birth status (i.e., VPT vs. FT) on 
PLAGL1 mean methylation at birth, while Model B compared PLAGL1 mean methylation at 
comparable term-equivalent age in both groups of infants. Model B included VPT infants’ 
PLAGL1 methylation at NICU discharge and FT infants’ PLAGL1 methylation at birth. In both 
models, potential confounders (i.e., infants’ gender, maternal age, family SES, MTHFR 
polymorphism and, only for model B, post-conceptional age at the term-equivalent epigenetic 
sampling). Confounders were selected based on clinical relevance and preliminary account 
of multicollinearity (measured according to the Variance Inflation Factor, VIF). All analyses 
were conductedd using R Software [41] setting p < .05. 
RESULTS 
Socio-demographic variables for each of the two subgroups of participants are presented in 
Table 1. VPTs differed from FTs only in the variables associated with birth status. Gender 
distribution did not differ between groups (Χ2 = 0.39, p = .53). We have preliminary tested for 
gender-related differences in PLAGL1 methylation separately in the two groups. In VPT 
infants at birth, t-test was -.87 (p = .39) and it ranged between -1.04 and -.36 (ps > .10) for 
CpG-specific methylation. In VPT infants at discharge, t-test was .92 (p = .36) and it ranged 
between .57 and 1.24 (ps > .10) for CpG-specific methylation. In FT infants, the t-test for the 
overall PLAGL1 methylation was -.11 (p = .91) and t-test for CpG-specific methylation ranged 
between -1.03 and .49 (all ps > .10). 
Insert Table 1 here 
High birth-to-discharge correlations emerged for CpG-specific (Figure 1) and mean PLAGL1 
methylation (r = .61, p < .001) among VPT infants. VPT infants’ PLAGL1 mean methylation at 
birth and discharge did not correlate with gestational age at birth and length of NICU stay 
(|rs| < .17, ps > .21). 
Insert Figure 1 here 






CpG-specific (Figure 2) and mean PLAGL1 methylation (Figure 3) significantly differ between 
VPT and FT infants at birth. 
Insert Figure 2 and 3 here 
Mean PLAGL1 methylation was higher in FT infants at birth compared to VPT counterparts at 
birth (Table 2A) and at discharge (Table 2B). In both regression models (all VIFs < 2.6), no 
significant effect of the MTHFR polymorphism emerged on PLAGL1 mean methylation. 
Insert Table 2 here 
DISCUSSION 
The present study aimed to assess PLAGL1 methylation differences between VPT and FT 
infants. Results suggest that PLAGL1 methylation is lower in VPT infants compared to their 
FT counterparts, even when controlling for perinatal confounders. PLAGL1 methylation is 
known to play a role in cell growth suppression [34]. Although we cannot discriminate 
between causes and consequences in the present study, our findings might be suggestive of 
a potential association of PLAGL1 down-regulation and VPT birth which needs to be further 
tested in future prospective studies including both prenatal and post-natal period 
assessments. In absence of previous literature linking PLAGL1 methylation and preterm birth 
the present hypothesis needs to be tested in further studies. Nonetheless, the present 
findings further contribute to our knowledge of the impact of birth status on the imprinting 
epigenome of preterm infants, and suggests that altered PLAGL1 methylation might be 
considered as a factor involved in preterm delivery [32]. Additionally, meta-analytic evidence 
suggests that Plagl1 is a member of a sort of imprinted gene network which comprises 
multiple genes and other imprinted transcripts that are involved in fetal growth [34,42,43]. As 
in the present work we only examined methylation of a PLAGL1 region, we cannot directly 
contribute to the literature on the imprinted gene network [44]. Nonetheless, the notion that 
the PLAGL1 gene might be involved also in humans in the broader regulation of prenatal and 
post-natal growth appears consistent with the present findings. 
Moreover, PLAGL1 methylation was found to be lower in VPT infants both at birth and at 
discharge when their adjusted age would be comparable to a FT infant. In other words, VPT 






infants had lower PLAGL1 methylation when compared to FT infants at birth as well as when 
accounting for comparable post-conception age. Despite being preliminary, these findings 
sustain the hypothesis that DNA methylation at imprinting regions – i.e., the PLAGL1 gene - 
may potentially provide a deeper understanding of how epigenetic mechanisms contribute to 
VPT infants’ development. Previous research on stress-related genes (e.g., the serotonin 
transporter gene, SLC6A4) showed that the painful nature of NICU-related life-saving 
procedures (i.e., skin-breaking procedures) is significantly associated with a birth-to-
discharge methylation increase (11, e.g. SLC6A4,21,22). Conversely, based on the present 
study, it might be plausible to speculate that imprinted genes, like PLAGL1, might be less 
susceptible to epigenetic regulation as a result of environmental exposures. The persistence 
of a reduced methylation profile of the PLAGL1 imprinted gene even at the end of the 
hospitalization indirectly supports the hypothesis that the PLAGL1 hypo-methylation pattern 
might be inherent to VPT birth status and neither transient nor affected by the length of NICU 
stay. 
Of note, the PLAGL1 methylation difference observed between VPT and FT infants was not 
affected by genetic variants of the MTHFR. This finding is partially surprising given that, 
previous research associated the MTHFR polymorphism with human variations in 
methylation [16]. Nonetheless, the MTHFR polymorphism was not associated with PLAGL1 
methylation levels, not even in interaction with prematurity. The nature of the interactions 
between MTHFR and imprinted genes deserves further investigation specifically within the 
context of preterm birth.  
The study has limitations. The sample size is relatively small, even if the high homogeneity 
within the VPT group partially compensates for this limitation. Moreover, only VPT infants 
were included. Although this choice was made to ensure internal consistency of the findings, 
results cannot be extended directly to extreme preterm infants (gestational age < 28 weeks) 
or moderate preterm ones (gestational age > 32 weeks). Finally, due to the observational 
nature of the study we are not able to distinguish the direction of the association between 
PLAGL1 methylation and premature birth (i.e. to determine if PLAGL1 methylation can be 






considered a cause, a consequence or a correlated event of premature birth). Future 
research should focus on the investigation of the role played by PLAGL1 methylation in 
preterm birth and the associated physiologic processes. 
In conclusion, this study demonstrates that PLAGL1 methylation is relatively constant during 
infants’ hospitalization after premature birth. Future studies are warranted to investigate: a) 
whether PLAGL1 hypo-methylation is a stable and reliable index of epigenetic processes 
occurring at imprinting regulatory regions in preterm birth; b) whether altered methylation of 
imprinted genes is stable across development in VPT infants. Moreover, the functional 
consequences of reduced PLAGL1 methylation in VPT infants are not known and the effects 
of this hypo-methylation profile on health and disease of VPT infants later in life may be a 
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Figure 1. Heat map of the correlations of methylation of each CpG site between birth and 
discharge for VPT. 
Figure 2. Forest plot to show descriptive values of the methylation (proportion) of each CpG 
site and confrontation between VPT and FT. Note. Blue lines and squares show the 
comparison between FT methylation at birth and VPT methylation at birth. Red lines and 
circles show the confrontation between FT methylation at birth and VPT methylation at 
discharge. FT, full-term; VPT, very preterm. 
Figure 3. Differences in mean methylation between groups. Note. FT, Full-Term; VPT, Very 
Preterm. 
 





1. The study of specific genes methylation to research on very preterm (VPT) birth holds 
promises of being beneficial for scientific knowledge and clinical practice 
2. Previous research documented that early stress exposure during the hospitalization might 
affect the methylation of stress-related genes in preterm infants 
3. Here we assessed methylation of an imprinted gene (i.e., PLAGL1) involved in fetal 
development at birth and at discharge in VPT infants and in full-term (FT) controls 
4. A significant pattern of hypo-methylation emerged in VPT infants at birth 
5. Additionally, this pattern was maintained at discharge, even controlling for variables related 
to the hospitalization 
6. These findings suggest that the methylation of the PLAGL1 gene might be involved in 
preterm birth and it might be a stable marker of VPT delivery even at discharge 
7. Future basic and clinical studies are needed to assess the behavioral and neurological 
consequences of PLAGL1 hypo-methylation in VPT infants 




























Gestational age (weeks) 
 
39.62 1.15  30.39 1.88  .50 < .001 
Apgar score at minute 1  9.92 .28  6.60 1.49  28.50 < .001 
Birth weight (grams)  3402.59 418.91  1395.75 342.21  .00 < .001 










Maternal age (years) 
 33.83 4.41  35.73 3.59  908.00 .14 
Maternal education (years of study)  14.81 3.75  16.06 2.33  571.00 .13 
Family SES  66.48 20.65  62.14 14.98  635.00 .23 
          
  N %  N %    
          
Causes of preterm birth          
          
Spontaneous preterm birth  14 25.0  NA NA    
Spontaneous labor with intact membranes  8 14.3  NA NA    
Premature rupture of membranes (pPROM)  6 10.7  NA NA    
          
Medically indicated preterm birth (maternal/fetal indication)  42 75.0  NA NA    
Pre-eclampsia  14 25.0  NA NA    
Intrahepatic cholestasis during pregnancy (ICP)  6 10.7  NA NA    
Maternal disease a  4 7.1  NA NA    
Placental causes b  6 10.7  NA NA    
Intrauterine growth restriction (IUGR)  5 8.9  NA NA    




Abnormal blood flow patterns in fetal circulation (fetal distress)  4 7.1  NA NA    
Multiple gestation complicated by twin-twin transfusion 
syndrome (TTTS) 
 3 5.4  NA NA    
          
 
Note. FT, Full-Term; VPT, Very Preterm; CI, Confidence Interval, NICU, Neonatal Intensive Care Unit; SES, Socio-Economic Status; a Acute renal 
disease or bowel perforation; b Placental abruption or placenta praevia. 




Table 2. Regression models testing the effect of Birth status (i.e., FT vs. VPT) on PLAGL1 mean methylation at birth (A) and at term-equivalent age 
(B) controlling for the MTHFR polymorphism. 
(A) R2 F p 
 
b SE t p 
         
Model .27 5.51 < .001 
     
         
Birth status 
    
.09 .02 4.85 < .001 
Infant's gender 
    
.01 .02 .66 .51 
Maternal age 
    
.001 .002 .55 .59 
Family SES 
    
.0005 .0005 .99 .33 
MTHFR polymorphism 
    
.01 .02 .32 .75 
(B) R2 F p 
 
b SE t p 
        
Model .18 2.7 < .05 
     
         
Birth Status 
    
.14 .04 3.27 < .011 
Post-conception age 
    
.001 .001 1.38 .17 
Infant's gender 
    
.03 .02 1.38 .17 
Maternal age 
    
.003 .003 .87 .39 
Family SES 
    
.0001 .001 .18 .86 
MTHFR polymorphism 
    
-.01 .03 -.51 .61 
 
Note. VPT, very preterm; FT, full-term; SES, Socio-Economic Status; Birth status, 0 = VPT, 1 = FT; Infant’s gender, 0 = males, 1 = females; MTHFR 
polymorphism, 0 = GA/AA, 1 = GG. 
 
 







Figure 1. Heat map of the correlations of methylation of each CpG site between birth and discharge for VPT. 
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Figure 2. Forest plot to show descriptive values of the methylation (proportion) of each CpG site and 
confrontation between VPT and FT. Note. Blue lines and squares show the comparison between FT 
methylation at birth and VPT methylation at birth. Red lines and circles show the confrontation between FT 
methylation at birth and VPT methylation at discharge. FT, full-term; VPT, very preterm.  
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Figure 3. Differences in mean methylation between groups. Note. FT, Full-Term; VPT, Very Preterm.  
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